RevMed Pharmaceuticals

Revolution Medicines is a clinical-stage oncology company focused on developing novel therapies that inhibit frontier targets within the RAS pathway. The company's proprietary Tri-Complex Technology platform enables the discovery of 'RAS(ON)' inhibitors, which are designed to bind directly to the active, GTP-bound state of RAS proteins. Their lead candidate, RMC-6236, is a multi-RAS inhibitor currently in late-stage clinical development for various RAS-mutated solid tumors, including pancreatic and lung cancers. By targeting the active state of the protein, Revolution Medicines aims to provide more comprehensive and durable responses for patients with difficult-to-treat cancers driven by RAS mutations.